Isoniazid-Isatin Hydrazone Derivatives: Synthesis, Antitubercular Activity and Molecular Docking Studies
DOI:
https://doi.org/10.48048/tis.2021.39Keywords:
Antitubercular, Hydrazone, Isatin, Isoniazid, Molecular dockingAbstract
This study examined the synthesis of isoniazid-isatin hydrazone derivatives 5-7, followed by an investigation on the in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv, and molecular docking. A yield of 81 - 92 % of these compounds was achieved, with structural characterization by spectroscopic methods (FTIR, NMR, HRMS). The in vitro antitubercular activity was evaluated against M. tuberculosis H37Rv, and the highest effect was observed in compound 7, with a minimum inhibitory concentration (MIC) of 0.017 mM, lower than rifampicin (MIC 0.048 mM), which served as the positive control. In addition, the molecular docking of 5-7 was performed to visualize the interaction of isoniazid-isatin hydrazone derivatives with the active site of InhA receptor, which was in agreement with the experimental data. The hydrogen bonding with Ser94 and pi-pi interaction with Phe41 and/or Phe97 on the InhA active site was pivotal for the antitubercular activity.
HIGHLIGHTS
- Tuberculosis caused by Mycobacterium tuberculosis is one of the top ten leading causes of death globally
- The first and second lines of antituberculosis drugs are the prevalent treatment for this disease, but they show several drawbacks and are exacerbated by the occurrence of drug resistance
- The isoniazid-isatin hydrazone derivatives were designed through molecular hybridization and synthesized effectively and exhibited moderate to high activity against tuberculosis H37Rv
- Molecular docking study demonstrated that the hydrogen bonding with Ser94 and the pi-pi interaction with Phe41 and/or Phe97 are important for antitubercular activity
GRAPHICAL ABSTRACT
Downloads
Metrics
References
T Aboul-Fadl, FAH Mohammed and EAS Hassan. Synthesis, antitubercular activity and pharmacokinetic studies of some Schiff bases derived from 1-alkylisatin and isonicotinic acid hydrazide (INH). Arch. Pharm. Res. 2003; 26, 778-84.
YQ Hu, S Zhang, F Zhao, C Gao, LS Feng, ZS Lv, Z Xu and X Wu. Isoniazid derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017; 133, 255-67.
PFM Oliveira, B Guidetti, A Chamayou, C Andre-Barres, J Madacki, J Kordulakova, G Mori, BS Orena, LR Chiarelli, MR Pasca, C Lherbet, C Carayon, S Massou, M Baron and M Baltas. Mechanochemical synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. Molecules 2017; 22, 1457.
World Health Organization, Global Tuberculosis Report 2019, Available at: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf, accessed December 2019.
D Jiang, GQ Wang, X Liu, Z Zhang, LS Feng and ML Liu. Isatin derivatives with potential antitubercular activities. J. Heterocycl. Chem. 2018; 55, 1263-79.
MA Elhakeem, AT Taher and SM Abuel-Maaty. Synthesis and anti-mycobacterial evaluation of some new isonicotinylhydrazide analogues. Bull. Facul. Pharm.Cairo Univ. 2015; 53, 45-52.
A Atta, S Fahmy, O Rizk, D Sriram, MA Mahran and IM Labouta. Structure-based design of some isonicotinic acid hydrazide analogues as potential antitubercular agents. Bioorg.Chem. 2018; 80, 721-32.
D Zhang, Y Lin, X Chen, W Zhao, D Chen, M Gao, Q Wang, B Wang, H Huang, Y Lu and Y Lu. Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold. Bioorg. Chem. 2019; 85, 229-39.
PS Salve, SG Alegaon and D Sriram. Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors. Bioorg. Med. Chem. Lett. 2017; 27, 1859-66.
SM Kishk, KJ McLean, S Sood, MA Helal, MS Gomaa, I Salama, SM Mostafa, LPSD Carvalho, AW Munro and C Simons. Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1. Bioorg. Med. Chem. 2019; 27, 1546-61.
OG Shaaban, DAE Issa, AA El-Tombary, SMAE Wahab, AEA Wahab and IA Abdelwahab. Synthesis and molecular docking study of some 3,4-dihydrothieno[2,3-d]pyrimidine derivatives as potential antimicrobial agents. Bioorg. Chem. 2019; 88, 102934.
Z Xu, S Zhang, C Gao, J Fan, F Zhao, ZS Lv and LS Feng. Isatin hybrids and their anti-tuberculosis activity. Chin. Chem. Lett. 2017; 28, 159-67.
T Wang, Y Tang, Y Yang, Q An, Z Sang, T Yang, P Lium T Zhang, Y Deng and Y Luo. Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold. Bioorg. Med. Chem. Lett. 2018; 28, 2084-90.
K Han, Y Zhou, F Liu, Q Guo, P Wang, Y Yang, B Song, W Liu, Q Yao, Y Teng and P Yu. Design, synthesis and in vitro cytotoxicity evaluation of 5-(2-carboxyethenyl)isatin derivatives as anticancer agents. Bioorg. Med. Chem. Lett. 2014; 24, 591-4.
Y Xu, J Guan, Z Xu and S Zhao. Design, synthesis and in vitro anti-mycobacterial activities of homonuclear and heteronuclear bis-isatin derivatives. Fitoterapia 2018; 127, 383-6.
A Saxena, S Sharma and A Husain. Antimicrobial and anti-tubercular activity of some new indole derivatives. World J. Pharm. Sci. 2015; 3, 1877-82.
S Ke, L Shi and Z Yang. Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents. Bioorg. Med. Chem. Lett. 2015; 25, 4628-31.
V Eggadi, U Kulandaivelu, SBB Sheshagiri and VR Jupalli. Evaluation of antioxidant, antimicrobial and anticancer activity of thiazole tagged isatin hydrazones. J. Pharmaceut. Chem. 2016; 3, 4-9.
T Aboul-Fadl, MK Abdel-Hamid and AF Youssef. Schiff bases of indoline-2,3-dione (isatin) derivatives as efficient agents against resistant strains of Mycobacterium tuberculosis. Der Pharma Chemica 2015; 7, 217-25.
WM Eldehna, M Fares, MM Abdel-Aziz and HA Abdel-Aziz. Design, synthesis and antitubercular activity of certain nicotinic acid hydrazides. Molecules 2015; 20, 8800-15.
SB Kumar, M Ravinder, G Kishore, VJ Rao, P Yogeeswari and D Sriram. Synthesis, antitubercular and anticancer activity of new Baylis-Hillman adduct-derived N-cinnamyl-substituted isatin derivatives. Med. Chem. Res. 2014; 23, 1934-40.
UK Singh, SN Pandeya, A Singh, BK Srivastava and M Pandey. Synthesis and antimicrobial activity of Schiff’s and N-Mannich bases of isatin and its derivatives with 4-amino-N-carbamimidoyl benzene sulfonamide. Int. J. Pharmaceut. Sci. Drug Res. 2010; 2, 151-4.
SS Swathy, RS Joseyphus, VP Nisha, N Subhadrambika and K Mohanan. Synthesis, spectroscopic investigation and antimicrobial activities of some transition metal complexes of a [(2-hydroxyacetophenone)-3-isatin]-bishydrazone. Arab. J. Chem. 2016; 9, S1847-S1857.
T Aboul-Fadl, FAS Bin-Jubair and O Aboul-Wafa. Schiff bases of indoline-2,3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building. Eur. J. Med.Chem. 2010; 45, 4578-86.
KHME Tehrani, M Hashemi, M Hassan, F Kobarfard and S Mohebbi. Synthesis and antibacterial activity of Schiff bases of 5-substituted isatins. Chin. Chem. Lett. 2016; 27, 221-5.
P Pakravan, S Kashanian, MM Khodaei and FJ Harding. Biochemical and pharmacological characterization of isatin and its derivatives: From structure to activity. Pharmacol. Rep. 2013; 65, 313-35.
L Yurttas, M Ertas, MY Cankilic and S Demirayak. Synthesis and antimycobacterial activity evaluation of isatin-derived 3- [(4-aryl-2-thiazolyl])hydrazone]-1H-indol-2,3-diones. Acta Pharm. Sci. 2017; 55, 51-8.
T Aboul-Fadl and FAS Bin-Jubair. Anti-tubercular activity of isatin derivatives. Int. J. Res. Pharmaceut. Sci. 2010; 1, 113-26.
WM El-Sayed, T Aboul-Fadl and MR Franklin. Effects of isatin-isoniazid derivatives on drug metabolizing and chemoprotective enzymes in mice. Drug Dev. Res. 2010; 71, 313-22.
MRG Fahmi, L Khumaidah, TK Ilmiah, A Fadlan and M Santoso. 2-Thiophenecarboxylic acid hydrazide derivatives: synthesis and anti-tuberculosis studies. IOP Conf. Ser. Mater. Sci. Eng. 2018; 349, 012039.
E Pahlavani, H Kargar and NS Rad. A study on antitubercular and antimicrobial activity of isoniazid derivative. Zahedan J. Res. Med. Sci. 2015; 17, e1010.
SE Adeniji, S Uba and A Uzairu. Quantitative structure–activity relationship and molecular docking of 4-alkoxy-cinnamic analogues as anti-mycobacterium tuberculosis. J. King Saud Univ. Sci. 2020; 32, 67-74.
SE Adeniji, S Uba and A Uzairu. Theoretical modeling for predicting the activities of some active compounds as potent inhibitors against Mycobacterium tuberculosis using GFA-MLR approach. J. King Saud Univ. Sci. 2020; 32, 575-86.
R Wang, X Yin, Y Zhang and W Yan. Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. Eur. J. Med.Chem. 2018; 156, 580-6.
E Stratan, N Turcan, V Crudu, E Romancenco, T Cotelea, GM Nitulescu, C Chirita and L Morusciag. Biological evaluation of new 2-phenethylbenzoyl thiourea derivatives as antituberculosis agents. Farmac. 2018; 66, 97-106.
B Thomas and J Harindran. Design, Synthesis and evaluation of antitubercular activity of Mannich bases of isoniazid-containing thiazolidin-4-one rings. Res. Rev. J. Pharmaceut. Sci. 2016; 7, 1-12.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
